Showing results (471-480 of 617) with videos related to

Sort By:
Pageof 62
Cancer|May 1, 1986
Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin, and cisplatinD M Gershenson, J J Kavanagh, L J Copeland, et al.
Gynecologic Oncology|March 6, 2012
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tubeIgnacio Romero Noguera, Charlotte C Sun, Russell R Broaddus, et al.
Cancer Biology & Therapy|August 17, 2012
Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3Siqing Fu, Yanfang Li, Jie Huang, et al.
Gynecologic Oncology|December 7, 2002
Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?Charlotte C Sun, Diane C Bodurka, Michele L Donato, et al.
Annals of Internal Medicine|September 1, 1986
Melphalan may be a more potent leukemogen than cyclophosphamideM H Greene, E L Harris, D M Gershenson, et al.
Molecular Cell|December 5, 2023
ER chaperones use a protein folding and quality control glyco-codeKevin P Guay, Haiping Ke, Nathan P Canniff, et al.
Molecular and Cellular Biochemistry|March 28, 2001
Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicityA Castilleja, N E Ward, C A O'Brian, et al.
Physical Review Letters|August 16, 2020
Parity-Protected Superconductor-Semiconductor QubitT W Larsen, M E Gershenson, L Casparis, et al.
Oncotarget|August 4, 2016
Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cellsSuet-Yan Kwan, Xuanjin Cheng, Yvonne T M Tsang, et al.
Gynecologic Oncology|May 24, 2005
Fifth International Conference on Ovarian Cancer: challenges and opportunitiesAnil K Sood, Nadeem R Abu-Rustum, Richard R Barakat, et al.
Pageof 62